Stock NXTC NEXTCURE, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus NextCure, Inc.

Equities

NXTC

US65343E1082

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-26 pm EDT 		5-day change 1st Jan Change
1.35 USD +4.65% Intraday chart for NextCure, Inc. -15.62% +18.42%
Apr. 08 NextCure, Inc. and LigaChem Biosciences, Inc. Present Preclinical Data on B7-H4 Antibody Drug Conjugate At AACR 2024 CI
Apr. 04 NextCure, Inc. Appoints Rakesh Dixit to Scientific Advisory Board CI

Evolution of the average Target Price on NextCure, Inc.

Price target over the last 5 years

History of analyst recommendation changes

5de3.A6xgU-66ltfVXEgaUVVvVbskMeJILKO1AE02v9y055k.RIEYFtfr2YegZX97NRAGIuRgCacZfpH9VCVv_qj10eBOzg4ZgNPUppwOAQ~2b10dd13e53dcedfb24768a771d996ee

Analyst Recommendations on NextCure, Inc.

HC Wainwright Initiates NextCure With Buy Rating, $7 Price Target MT
BTIG Lowers NextCure's Price Target to $8 From $27, Maintains Buy Rating MT
Needham Lowers NextCure's Price Target to $6 From $12, Maintains Buy Rating MT
Roth Capital Lowers NextCure's Price Target to $4 From $6, Maintains Neutral Rating MT
Ladenburg Downgrades NextCure to Neutral From Buy MT
Piper Sandler Adjusts Price Target on NextCure to $6 From $13, Maintains Overweight Rating MT
Truist Securities Adjusts NextCure's Price Target to $15 From $19, Reiterates Buy Rating MT
Piper Sandler Lowers NextCure's Price Target to $13 From $21, Maintains Overweight Rating MT
Ladenburg Thalmann Initiates NextCure at Buy With $16 Price Target MT
Needham Adjusts Price Target on NextCure to $14 from $30, Keeps Buy Rating MT
NEXTCURE : Piper Sandler Adjusts NextCure's Price Target to $21 From $26, Maintains Overweight Rating MT
NEXTCURE : Truist Securities Upgrades NextCure to Buy From Hold; Price Target is $19 MT
NEXTCURE : BofA Securities Downgrades NextCure to Underperform From Neutral, Adjusts Price Target to $10 From $13 MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
4
Last Close Price
1.35 USD
Average target price
5 USD
Spread / Average Target
+270.37%
High Price Target
8 USD
Spread / Highest target
+492.59%
Low Price Target
3 USD
Spread / Lowest Target
+122.22%

Consensus detail

Consensus revision (last 18 months)

Analysts covering NextCure, Inc.

HC Wainwright
Piper Sandler
Ladenburg Thalmann
Roth Capital Partners
Needham & Co.
BTIG
Truist Securities
BofA Securities

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. NXTC Stock
  4. Consensus NextCure, Inc.